1887

Abstract

Antimicrobial resistance in spp. is of grave concern, more so in quinolone-resistant and extended-spectrum -lactamase (ESBL)-producing isolates that cause complicated infections. The MIC of azithromycin, ciprofloxacin, cefixime, cefepime, ceftriaxone, gatifloxacin, imipenem, levofloxacin, meropenem and ofloxacin (E-test strip) and tigecycline and faropenem (agar dilution) against 210 spp. was determined. MIC (defined as the antimicrobial concentration thatinhibited growth of 90 % of the strains) of the carbapenems (imipenem and meropenem) for Typhi and Paratyphi A was 0.064 μg ml. MIC of faropenem was 0.25 μg ml for . Typhi, . Paratyphi A and Typhimurium. The MIC of azithromycin for all spp. ranged from 8 to 16 μg ml. Tigecycline showed an MIC of 2 μg ml for . Typhi, 1 μg ml for Paratyphi A and 4 μg ml for Typhimurium. We concluded that tigecycline and the carbapenems are likely to have roles in the final stage of treatment of quinolone-resistant and ESBL-producing multidrug-resistant salmonellae.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.47853-0
2009-03-01
2020-04-06
Loading full text...

Full text loading...

/deliver/fulltext/jmm/58/3/337.html?itemId=/content/journal/jmm/10.1099/jmm.0.47853-0&mimeType=html&fmt=ahah

References

  1. AitMhand R., Soukri A., Moustaoui N., Amarouch H., ElMdaghri N., Sirot D., Benbachir M. 2002; Plasmid-mediated TEM-3 extended-spectrum β -lactamase production in Salmonella typhimurium in Casablanca. J Antimicrob Chemother 49:169–172 [CrossRef]
    [Google Scholar]
  2. Brown S. D., Traczewski M. M. 2007; Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control. J Clin Microbiol 45:2173–2179 [CrossRef]
    [Google Scholar]
  3. Butler T., Sirdhar C. B., Daga M. K., Pathak K., Pandit R. B., Khakhria R., Potkar C. N., Zelasky M. T. 1999; Treatment of typhoid fever with azithromycin vs chloramphenicol in a randomized multicentre trial in India. J Antimicrob Chemother 44:243–250 [CrossRef]
    [Google Scholar]
  4. Capoor M. R., Nair D., Hasan A. S., Aggarwal P., Gupta B. 2006; Narrowing therapeutic options in typhoid fever, India. Southeast Asian J Trop Med Public Health 37:1170–1174
    [Google Scholar]
  5. Capoor M. R., Rawat D., Nair D., Hasan A. S., Deb M., Aggarwal P., Pillai P. K. 2007; In vitro activity of azithromycin, newer quinolones and cephalosporins in ciprofloxacin-resistant Salmonella causing enteric fever. J Med Microbiol 56:1490–1494 [CrossRef]
    [Google Scholar]
  6. CLSI 2006; Performance Standards for Antimicrobial Susceptibility Testing , 17th Informational Supplement. CLSI Document M100–S16 26: Wayne, PA: CLSI;
    [Google Scholar]
  7. Cooke F. J., Wain J., Threlfall E. J. 2006; Fluoroquinolone resistance in Salmonella enterica serovar Typhi. BMJ 333:353–354
    [Google Scholar]
  8. Egorova S., Kaftyreva L., Grimont P. A. D., Weill F. X. 2007; Prevalence and characterization of extended-spectrum cephalosporin-resistant nontyphoidal Salmonellae isolates in adults in Saint Petersburg, Russia. (2002–2005). Microb Drug Resist 13:102–107 [CrossRef]
    [Google Scholar]
  9. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee 2006; EUCAST technical note on tigecycline. Clin Microbiol Infect 12:1147–1149 [CrossRef]
    [Google Scholar]
  10. Frenck R. W. Jr, Mansour A., Nakhla I., Sultan Y., Putnam S., Wierzba T., Morsy M., Knirsch C. 2004; Short course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. Clin Infect Dis 38:951–957 [CrossRef]
    [Google Scholar]
  11. Fritsche T. R., Strabala P. A., Sader H. S., Dowzicky M. J., Jones R. N. 2005; Activity of tigecycline tested against a global collection of Enterobacteriaceae including tetracycline-resistant isolates. Diagn Microbiol Infect Dis 52:209–213 [CrossRef]
    [Google Scholar]
  12. Girgis N. I., Butler T., Frenck R. W., Sultan Y., Brown F. M., Tribble D., Johnson R. B., Khakhria R. 1999; Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob Agents Chemother 43:1441–1444
    [Google Scholar]
  13. Harish B. N., Menezes G. A., Sarangapani K., Parija S. C. 2006; Fluoroquinolone resistance among Salmonella enterica serovar Paratyphi A in Pondicherry. Indian J Med Res 124:585–587
    [Google Scholar]
  14. Joshi S., Amarnath S. K. 2007; Fluoroquinolone resistance in S . Typhi and S . Paratyphi A in Banglore, India. Trans R Soc Trop Med Hyg 101:308–310 [CrossRef]
    [Google Scholar]
  15. Kownhar H., Shankar E. M., Rajan R., Rao U. A. 2007; Emergence of nalidixic acid-resistant Salmonella enterica serovar Typhi resistant to ciprofloxacin in India. J Med Microbiol 56:136–137 [CrossRef]
    [Google Scholar]
  16. Livermore D. M. 2005; Tigecycline: What is it, and where should it be used?. J Antimicrob Chemother 56:611–614 [CrossRef]
    [Google Scholar]
  17. Morosini M. I., Garcia-Castillo M., Coque T. M., Valverde A., Novais A., Loza E., Baquero F., Canton F. 2006; Antibiotic coresistance in extended spectrum- β -lactamase producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 50:2695–2699 [CrossRef]
    [Google Scholar]
  18. Old D. C. 1996; Salmonella . In Mackie and McCartney Practical Medical Microbiology , 14th edn. pp 385–404 Edited by Collee J. G., Fraser A. G., Marmion B. P., Simmons A. Edinburgh: Churchill Livingstone;
    [Google Scholar]
  19. Otkun M., Erdem B., Akata F., Tatman-Otkun M., Gerceker D., Yagci S., Ozkan E. 2001; Antibiotic resistance patterns and plasmid profiles of Salmonella typhimurium isolates in Turkey. Eur J Clin Microbiol Infect Dis 20:206–209 [CrossRef]
    [Google Scholar]
  20. Parry C. M., Ho V. A., Phuong L. T., Bay P. V., Lanh M. N., Tung L. T., Tham N. T., Wain J., Hien T. T. 2007; A randomized controlled comparison of ofloxacin, azithromycin and ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother 51:819–825 [CrossRef]
    [Google Scholar]
  21. Piddock L. J. V., Johnson M. M., Webber M. A. 2003; Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria. J Antimicrob Chemother 52:500–502 [CrossRef]
    [Google Scholar]
  22. Pokharel B. M., Koirala J., Dahal R. K., Mishra S. K., Khadga P. K., Tuladhar N. R. 2006; Multidrug-resistant and extended-spectrum β -lactamase (ESBL)-producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and a search for newer alternatives. Int J Infect Dis 10:434–438 [CrossRef]
    [Google Scholar]
  23. Saha S. K., Talukder S. Y., Islam M., Saha S. 1999; A highly ceftriaxone resistant Salmonella typhi in Bangladesh. Pediatr Infect Dis J 18:387 [CrossRef]
    [Google Scholar]
  24. Sorbera L. A., Del Fresno N., Castaner R. M., Rabasseda X. 2002; Faropenem daloxate. Drugs Fut 27:223 [CrossRef]
    [Google Scholar]
  25. Sun H. Y., Tseng S. P., Hsueh P. R., Hung C. C., Hsieh S. M., Teng L. J., Ho S. W. 2005; Occurrence of ceftriaxone resistance in ciprofloxacin-resistant Salmonella enterica serotype Choleraesuis isolates causing recurrent infection. Clin Infect Dis 40:208–209 [CrossRef]
    [Google Scholar]
  26. Weill F. X., Guesnier F., Guibert V., Timinouni M., Demartin M., Polomack L., Grimont P. A. D. 2006; Multidrug resistance in Salmonella enterica serotype Typhimurium from humans in France (1993 to 2003). J Clin Microbiol 44:700–708 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.47853-0
Loading
/content/journal/jmm/10.1099/jmm.0.47853-0
Loading

Data & Media loading...

Most cited this month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error